Tower Research Capital LLC TRC Buys 5,730 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Tower Research Capital LLC TRC lifted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 142.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 9,756 shares of the biopharmaceutical company’s stock after acquiring an additional 5,730 shares during the period. Tower Research Capital LLC TRC’s holdings in Ocular Therapeutix were worth $44,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Deltec Asset Management LLC boosted its position in shares of Ocular Therapeutix by 18.5% during the 4th quarter. Deltec Asset Management LLC now owns 2,443,607 shares of the biopharmaceutical company’s stock worth $10,898,000 after purchasing an additional 381,810 shares in the last quarter. Legato Capital Management LLC bought a new position in shares of Ocular Therapeutix during the 4th quarter worth about $667,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Ocular Therapeutix by 350.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,192 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 7,152 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Ocular Therapeutix by 96.4% during the 3rd quarter. GSA Capital Partners LLP now owns 233,582 shares of the biopharmaceutical company’s stock worth $733,000 after purchasing an additional 114,629 shares in the last quarter. Finally, Graham Capital Management L.P. bought a new position in shares of Ocular Therapeutix during the 3rd quarter worth about $299,000. Institutional investors own 59.21% of the company’s stock.

Ocular Therapeutix Stock Up 16.9 %

NASDAQ:OCUL traded up $0.85 on Thursday, hitting $5.87. The stock had a trading volume of 3,474,504 shares, compared to its average volume of 2,252,016. The company has a debt-to-equity ratio of 0.82, a quick ratio of 6.59 and a current ratio of 6.66. The stock has a market cap of $908.27 million, a P/E ratio of -4.60 and a beta of 1.47. Ocular Therapeutix, Inc. has a 1 year low of $2.00 and a 1 year high of $11.31. The firm’s fifty day simple moving average is $8.41 and its two-hundred day simple moving average is $5.44.

Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28). The firm had revenue of $14.80 million during the quarter, compared to analyst estimates of $15.31 million. Ocular Therapeutix had a negative net margin of 138.15% and a negative return on equity of 321.12%. Analysts predict that Ocular Therapeutix, Inc. will post -0.68 earnings per share for the current year.

Insider Buying and Selling at Ocular Therapeutix

In other news, major shareholder Summer Road Llc acquired 930,851 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was purchased at an average price of $7.52 per share, for a total transaction of $6,999,999.52. Following the purchase, the insider now owns 8,591,401 shares in the company, valued at approximately $64,607,335.52. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 5.50% of the company’s stock.

Analyst Ratings Changes

OCUL has been the topic of a number of research analyst reports. Bank of America initiated coverage on shares of Ocular Therapeutix in a research report on Friday, February 9th. They set a “buy” rating and a $15.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Ocular Therapeutix in a research report on Friday, April 19th. Piper Sandler raised their price target on shares of Ocular Therapeutix from $10.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, February 26th. StockNews.com cut shares of Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Friday, April 5th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $24.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, April 16th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $17.60.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.